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Summary
Background Androgens are thought to have an adverse effect on female scalp hair
growth. However, our clinical experience of androgen replacement therapy in
women with androgen deﬁciency, in which hair loss was seldom reported, led
us to question this concept.
Objectives To evaluate the effect of subcutaneous testosterone therapy on scalp hair
growth in female patients.
Methods A total of 285 women, treated for a minimum of 1 year with subcutane-
ous testosterone implants for symptoms of androgen deﬁciency, were asked to
complete a survey that included questions on scalp and facial hair. Age, body
mass index (BMI) and serum testosterone levels were examined.
Results Out of the 285 patients, 76 (27%) reported hair thinning prior to treat-
ment; 48 of these patients (63%) reported hair regrowth on testosterone therapy
(responders). Nonresponders (i.e. no reported hair regrowth on therapy) had
signiﬁcantly higher BMIs than responders (P =0 Æ05). Baseline serum testosterone
levels were signiﬁcantly lower in women reporting hair loss prior to therapy than
in those who did not (P =0 Æ0001). There was no signiﬁcant difference in serum
testosterone levels, measured 4 weeks after testosterone implantation, between
responders and nonresponders. No patient in this cohort reported scalp hair loss
on testosterone therapy. A total of 262 women (92%) reported some increase in
facial hair growth.
Conclusions Subcutaneous testosterone therapy was found to have a beneﬁcial effect
on scalp hair growth in female patients treated for symptoms of androgen deﬁ-
ciency. We propose this is due to an anabolic effect of testosterone on hair
growth. The fact that no subject complained of hair loss as a result of treatment
casts doubt on the presumed role of testosterone in driving female scalp hair loss.
These results need to be conﬁrmed by formal measurements of hair growth.
Thinning of hair is a common complaint in women. Its fre-
quency in the female population increases with age. Two
studies in caucasian women in the U.K. and U.S.A. reported
prevalence rates of reduced hair density of 3–6% in women
aged under 30 years, increasing to 29–42% in women aged
‡ 70 years.
1,2 Although diverse pathologies can cause hair
thinning, the most common diagnostic category is female pat-
tern hair loss (FPHL). This typically presents as a diffuse
reduction in hair density affecting the mid and frontal regions
of the scalp with preservation of the frontal hairline. Although
the distribution of hair loss in women is usually different
from that seen in male balding (male androgenetic alopecia),
the histopathological and dynamic changes in hair growth are
similar, and FPHL has long been regarded as the female
counterpart of male balding, giving rise to the term ‘female
androgenetic alopecia’.
3 Male balding is undoubtedly an
androgen-dependent genetically determined trait.
4 Observa-
tions in men with a genetic deﬁciency of 5a-reductase type 2
suggest that the active androgen in male balding is dihydrotes-
tosterone (DHT) rather than testosterone.
5 These men have
ambiguous genitalia with normal or high levels of circulating
testosterone but low DHT. They do not go bald and have
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male balding has been conﬁrmed by the positive response to
treatment in clinical trials of 5a-reductase inhibitors.
6,7
It is widely believed that androgens also have an adverse
effect on scalp hair growth in women, and the idea that FPHL
is an androgen-dependent trait remains prevalent. However, in
our clinical experience (R.G.), treating more than 1100 female
patients with over 10 000 subcutaneous testosterone pellet
insertions, hair thinning has rarely been reported. In this insti-
tutional review board (IRB)-approved study, pre- and post-
menopausal patients were treated with testosterone implants
for symptoms of ‘relative androgen deﬁciency’ including: a
diminished sense of well-being, dysphoric mood (sadness,
depression, anxiety, irritability), fatigue, decreased libido, hot
ﬂushes, bone loss, decreased muscle strength, changes in cog-
nition and memory, and insomnia. As part of a follow-up
questionnaire aimed at assessing clinical response to therapy,
patients were asked about their experience of hair loss before
and after testosterone treatment.
Subjects and methods
All patients in this study group are part of an ongoing 10-
year, prospective IRB-approved trial on the effect of subcuta-
neous testosterone implants on the incidence of breast cancer.
8
Pre- and postmenopausal patients were either self-referred or
referred by their physician to this private, clinical practice
(R.G.) for subcutaneous testosterone therapy for symptoms of
relative androgen deﬁciency including: hot ﬂushes, insomnia,
depressive mood, irritability, anxiety, premenstrual syndrome,
fatigue, memory loss, menstrual or migraine headaches, vagi-
nal dryness, sexual problems, urinary symptoms, pain and
bone loss.
Female patients treated with testosterone implant therapy
for at least 1 year, seen at the clinic between February and
April 2010, were accrued to this ‘follow-up’ questionnaire
study. All 285 eligible patients completed the clinical survey
and were offered serum testing. Written informed consent
was obtained from all patients.
Patients included in this study had received treatment with
subcutaneous testosterone implant therapy for 28Æ1±1 0 Æ4
months (range 12–56). Testosterone implants had been
inserted, on average, every 13Æ8±3 Æ8 weeks (i.e. when
symptoms returned). The mean testosterone implant dose in
this cohort of patients was 133Æ3±2 6 Æ8 mg.
Questionnaire
The questions on the survey regarding hair status were
designed to evaluate the patient’s perception of hair ‘thinning’
(hair loss) and her clinical response to testosterone implant
therapy. Two questions on the survey addressed scalp hair
(Table 1). The surveys were self-completed by the patient at
the time of their appointment. The medical staff was available
to assist patients.
Serum testosterone
Baseline serum testosterone levels were measured in 228 of
the 285 patients prior to beginning testosterone therapy. Base-
line testosterone levels were not available in 19 patients, and
38 patients had salivary hormone testing done. In addition,
patients were encouraged, but not required, to have serum
testosterone levels drawn 4 weeks after their testosterone pel-
lets were inserted. Total testosterone levels were measured
using liquid chromatography tandem mass spectrometry. The
intra-assay coefﬁcient of variation was 9%.
Statistical analysis
The statistical program R (R Development Core Team, 2009;
http://www.r-project.org/) was used for all data analysis.
Age was calculated using the patient’s birth-date and the sur-
vey completion (pellet implantation) date. The Wilcoxon test
was used to compare median age of patients who reported
‘hair thinning’ prior to therapy and those who did not.
Body mass index (BMI) was calculated using patients’
recorded height and weight at baseline, i.e. the initial visit,
prior to testosterone therapy, and again at follow-up, i.e. at
the date of the survey, on testosterone therapy.
Because hair loss is associated with insulin resistance and
obesity, the Wilcoxon test with the one-sided alternative was
used to determine if the distribution of BMI (baseline) was
greater in the group who reported ‘hair thinning’ prior to
Table 1 Questions in survey relating to scalp hair and effects of testosterone therapy
Question Available response
Did you have any thinning of scalp hair prior to therapy? Yes (Y) or no (N)
If hair thinning was reported (Y), the patient was then asked to respond to the
subsequent question:
Did testosterone therapy help hair regrowth on your scalp? Yes (Y), i.e. regrowth of hair on scalp or no
(N), i.e. no regrowth of hair on scalp
An additional question addressed potential side-effects from testosterone implant therapy:
Did you notice any negative or adverse side-effects from testosterone pellet therapy?
If (Y), the patient was asked to list the side-effect
Yes (Y) or no (N)
Patients were also questioned about the effect of testosterone therapy on facial hair:
Did facial hair increase? No increase, minimal, moderate, severe
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to compare mean BMI (follow-up) in patients who reported
‘hair regrowth’ on testosterone implant therapy and those
who did not.
To investigate whether baseline testosterone levels were
related to reported hair thinning, the Wilcoxon rank-sum test
was employed. The Kruskal–Wallis rank sum test was used to
determine if follow-up testosterone levels on therapy varied
signiﬁcantly among three patient cohorts: patients reporting
‘hair regrowth’ vs. ‘no hair regrowth’ vs. ‘no prior hair loss’.
Where relevant, results are given as mean ± SD.
Results
Out of 285 patients, 284 completed the survey (including the
questions addressing scalp hair); 283 responded yes (Y) or no
(N) to hair thinning prior to testosterone therapy. Only one
patient was ‘not sure’ if she had hair thinning prior to ther-
apy. Seventy-six of the 284 responders (26Æ8%) reported ‘hair
thinning’ prior to testosterone implant therapy; 48 of these 76
patients (63Æ2%) reported ‘hair regrowth’ on testosterone
therapy (Fig. 1). None of the subjects reported loss of hair
during treatment.
Patients who reported ‘hair thinning’ prior to therapy were
older (56Æ6±7 Æ82 years) than patients who reported ‘no hair
thinning’ prior to therapy (54Æ1±8 Æ01 years; W = 6657Æ5,
P =0 Æ05).
There was no difference in baseline BMI between women
who reported hair thinning prior to testosterone therapy
(25Æ45 ± 4Æ45 kg m
)2) and those who did not (25Æ15 ±
4Æ51 kg m
)2)( W = 7325, P =0 Æ20). However, patients who
reported ‘no hair regrowth’ on testosterone therapy had a sig-
niﬁcantly higher BMI (26Æ01 ± 4Æ04 kg m
)2) compared with
patients who reported ‘hair regrowth’ on testosterone therapy
(24Æ61 ± 4Æ24 kg m
)2)( W = 814Æ5, P =0 Æ05). Of patients
who reported ‘no hair regrowth’, 59Æ3% had a BMI > 25
kg m
)2 compared with 38Æ3% of patients who reported ‘hair re-
growth’. In addition, ﬁve of the 27 patients who reported ‘no
regrowth’ on therapy had confounding conditions: Hashimoto
thyroiditis (n = 2), thyroid-stimulating hormone (TSH) < 0Æ02
MIU mL
)1 (n = 1), documented iron deﬁciency (n = 2). In
contrast, only one of 48 patients who reported ‘hair regrowth’
on testosterone therapy had a TSH < 0Æ05 MIU mL
)1 and there
were no documented cases of thyroiditis or iron deﬁciency.
A total of 92Æ1% of the patients reported an increase in facial
hair growth on testosterone implant therapy with the majority
rating it as ‘minimal or moderate’ (85Æ7%) vs. ‘severe’ (6Æ4%).
Although some patients requested a lower dose of testosterone,
no one discontinued therapy for this reason.
Serum testosterone
Baseline serum testosterone levels were available for 228 of 285
patients. Follow-up testosterone levels, measured 4 weeks after
testosterone pellet implantation, were available on 154 patients.
Baseline serum testosterone levels were signiﬁcantly lower
in women who reported ‘hair thinning’ (14Æ18 ± 10Æ51
ng dL
)1) compared with women who reported ‘no hair thin-
ning’ (21Æ92 ± 15Æ69 ng dL
)1) prior to testosterone implant
therapy (W = 6966, P =0 Æ0001).
There was no signiﬁcant difference in serum testosterone
levels, measured 4 weeks after insertion of the subcutaneous
testosterone implant, between patients who reported ‘hair re-
growth’ (329Æ79 ± 110Æ14 ng dL
)1), patients who reported
‘no hair regrowth’ (300Æ16 ± 148Æ43 ng dL
)1) and patients
who had previously reported ‘no hair thinning prior to ther-
apy’ (295Æ88 ± 104Æ72 ng dL
)1) (Kruskal–Wallis v
2 =1 Æ25,
d.f. = 2, P =0 Æ53) (Fig. 2).
Furthermore, no patient in this cohort of patients reported
or listed ‘hair loss or thinning’ as a ‘negative or adverse side-
effect from testosterone pellet therapy’ despite therapeutic
serum testosterone levels four times greater, on average, than
the upper limit of endogenous production (72 ng dL
)1).
Discussion
The results of our study raise important questions about the
role of testosterone in causing hair loss in women. Several
investigators have reported that women with hair loss are
more likely to have elevated androgen levels or show an in-
creased frequency of other features of androgen excess than
women without hair loss. For example, Futterweit and col-
leagues
9 reported that 38Æ5% of 109 women with hair loss
had elevated androgen levels, and, in a series of 187 women,
Vexiau et al.
10 reported abnormal hormonal proﬁles, mostly of
minor degree, in 67% of those with hair loss alone and in
84% of women who were also hirsute. In a series of 89
women presenting to a trichology clinic with hair loss, 67%
Fig 1. Responses to questionnaire by study
participants (n = 285) treated with
subcutaneous testosterone implants.
  2011 The Authors
BJD   2011 British Association of Dermatologists 2012 166, pp274–278
276 Testosterone improves hair growth in androgen-deﬁcient women, R.L. Glaser et al.showed ultrasound evidence of polycystic ovaries compared
with 27% in a control group of 73 women, and 21% were
signiﬁcantly hirsute compared with 4% of controls.
11 An in-
creased frequency of insulin resistance has also been reported
in women with hair loss.
12 However, other investigators failed
to ﬁnd evidence of raised androgen levels in women with
FPHL,
13 and in all studies there is a variable proportion of
women with hair loss who do not show clinical or biochemi-
cal signs of androgen excess. The results of clinical trials of
antiandrogen therapy also provide no clear evidence for the
role of androgens in FPHL. In a 1-year placebo-controlled
study, ﬁnasteride 1 mg daily failed to prevent progression of
hair loss in postmenopausal women with FPHL.
14 Similarly, in
a trial comparing cyproterone acetate with topical minoxidil,
hair counts had fallen in the antiandrogen-treated group after
1 year, compared with an increase in hair counts in subjects
using minoxidil.
15 Subset analysis in this study did show a
positive response to cyproterone acetate in women with irreg-
ular menses, suggesting an androgenic aetiology for hair loss
in women with hyperandrogenism, but not in those without.
Some support for this idea comes from an Italian trial which
reported a small response to ﬂutamide (but not to ﬁnasteride
or cyproterone acetate) in hyperandrogenic women.
16
In view of the widely held concept that androgens have a
deleterious effect on scalp hair growth, the results of our
study were unexpected. The study was not designed to investi-
gate speciﬁcally the response of hair growth to androgen
replacement therapy, and we recognize the limitations of a
questionnaire in providing an objective measure of hair
growth. To conﬁrm our ﬁndings, formal assessment of hair
growth, e.g. using methods such as a phototrichogram, would
be needed. It is possible, for example, that a general positive
effect on wellbeing of testosterone replacement misled subjects
into believing that their hair growth had also improved. How-
ever, the fact that hair growth responded in the opposite
direction to that expected and that patients reporting hair loss
prior to therapy had lower testosterone levels than those not
reporting hair loss does provide support for the veracity of the
observation. Although a patient’s perception of hair thickness
and texture is subjective, only one of 284 female patients was
unsure of hair loss⁄thinning prior to testosterone therapy. Pre-
vious studies have shown that self-perception correlates with
investigator assessment and photography (Dr T.L. Dawson,
personal communication). In our experience, women are
acutely aware of changes in their hair.
Signiﬁcantly, no patient in this cohort, treated with contin-
uous testosterone for over 1 year, reported ‘hair loss or thin-
ning’ despite average serum testosterone levels of over
300 ng dL
)1, four times the upper limit of normal for endo-
genous production, and sufﬁcient to cause an increase in facial
hair growth in the majority.
A possible explanation of our results could be that testoster-
one has anabolic as well as virilizing properties. Although
these properties may overlap, the distinction is evident in men
with a genetic deﬁciency of 5a-reductase type 2. These men
have low circulating levels of DHT, but normal male levels of
testosterone. They show incomplete genital development,
reduced secondary sexual hair growth and absence of male
balding, yet have a normal male pattern of muscular and skel-
etal development.
5 Insulin, androgens and BMI (obesity) are
related in women both with and without polycystic ovary syn-
drome.
17 Insulin resistance, obesity and metabolic syndrome
are associated with increased 5a-reductase activity and hair
loss in both men and women.
12,18,19 Insulin also stimulates
testosterone biosynthesis, which may account for the higher
testosterone levels seen in this group of patients.
20 Perhaps
insulin resistance and subsequent increased 5a-reductase activ-
ity (i.e. elevated DHT) impact hair loss and virilization, rather
than testosterone. This is consistent with our ﬁndings –
women who reported ‘no hair regrowth’ on testosterone ther-
Fig 2. Week-4 serum testosterone levels
measured in 26 of 48 patients reporting ‘hair
regrowth’ on testosterone implant therapy, 18
of 27 patients reporting ‘no hair regrowth’ on
testosterone implant therapy and 110 of 195
patients reporting ‘no hair thinning’ prior to
testosterone therapy.
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reported ‘hair regrowth’ on testosterone therapy.
We suggest, therefore, that our results indicate that testos-
terone has a positive anabolic effect on hair growth, which is
distinct from a possible DHT-dependent deleterious role. The
hair follicle is certainly a site of vigorous protein synthesis –
the average human scalp produces around 13 km of hair per
year. Androgen production in women declines with age and
does not vary with menopause.
21 A woman aged 40 years has
half the mean plasma total testosterone of a 21-year-old.
22
Mean hair density and hair shaft diameter show a similar age-
related distribution in the female population
1 and the fall in
scalp hair density and hair shaft diameter, starting in the early
to mid-thirties, parallels androgen levels much more closely
than the common explanation relating female hair loss to
postmenopausal oestrogen deﬁciency.
In conclusion, our results suggest that the effect of andro-
gens on scalp hair growth in women is complex. Loss of hair
may occur in hyperandrogenic states, possibly due to similar
genetically determined DHT-driven mechanisms as occur in
male balding, although the only evidence of this in our study
was the lack of improvement in hair thinning in women with
high BMIs. However, androgen deﬁciency may also lead to
thinning hair due to loss of a more general testosterone-
dependent anabolic effect on hair growth. This observation
needs to be conﬁrmed but potentially opens the way for a
new approach to the treatment of female hair loss.
What’s already known about this topic?
• Androgens are implicated in causing scalp hair thinning
in women.
• Circulating androgen levels in the female population
decline from around 30 years of age.
• Scalp hair density and mean hair shaft diameter in the
female population decline from early to mid-thirties.
What does this study add?
• Treatment with testosterone in women with symptoms
of androgen deﬁciency improves scalp hair growth in a
high proportion of those reporting hair thinning prior
to treatment.
• Testosterone may have an anabol i ce f f e c to nh a i rg r o w t hi n
women with symptoms of androgen deﬁciency.
• No subject reported scalp hair loss on testosterone treat-
ment, casting doubt over the presumed role of testoster-
one in causing hair loss.
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